NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
Clinical Trials
16 trialsNCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06750952 2024-12-27
iTHYM
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06692062 2024-11-18
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Xiangya Hospital of Central South University
Phase NA Recruiting
NCT06189183 2024-02-16
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Recruiting
NCT03023319 2022-06-14
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Augusta University
Phase 1 Completed
NCT02420691 2020-10-30
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01165658 2020-01-02
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02364076 2019-12-13
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
Georgetown University
Phase 2 Unknown
NCT01364727 2019-04-16
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Stanford University
Phase 2 Completed
NCT03219554 2017-08-02
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
Samsung Medical Center
Phase 2 Unknown
NCT03078699 2017-03-13
Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment
Third Military Medical University
Phase NA Completed
NCT01312324 2016-04-20
Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
Samsung Medical Center
Phase 2 Completed
NCT01163552 2014-06-13
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
St. Luke's-Roosevelt Hospital Center
Phase 2 Completed
NCT00369889 2014-06-03
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
Indiana University
Phase 2 Completed
NCT00990535 2009-10-07
HIDONET
Federico II University
Phase 2 Completed